

# Lei You

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/493159/publications.pdf>

Version: 2024-02-01

93  
papers

4,414  
citations

109264

35  
h-index

123376

61  
g-index

101  
all docs

101  
docs citations

101  
times ranked

6402  
citing authors

#	ARTICLE	IF	CITATIONS
1	CREPT serves as a biomarker of poor survival in pancreatic ductal adenocarcinoma. <i>Cellular Oncology (Dordrecht)</i> , 2021, 44, 345-355.	2.1	2
2	Clinicopathological and prognostic significance of ubiquitin-specific peptidase 15 and its relationship with transforming growth factor- $\beta$ 2 receptors in patients with pancreatic ductal adenocarcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 507-515.	1.4	7
3	Preclinical models of pancreatic ductal adenocarcinoma: challenges and opportunities in the era of precision medicine. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 8.	3.5	13
4	Targeting hypoxic tumor microenvironment in pancreatic cancer. <i>Journal of Hematology and Oncology</i> , 2021, 14, 14.	6.9	198
5	Quantitative assessment of the diagnostic role of mucin family members in pancreatic cancer: a meta-analysis. <i>Annals of Translational Medicine</i> , 2021, 9, 192-192.	0.7	9
6	The Role of Mitochondria in the Chemoresistance of Pancreatic Cancer Cells. <i>Cells</i> , 2021, 10, 497.	1.8	28
7	Surgical Treatment for Postprandial Hypoglycemia After Roux-en-Y Gastric Bypass: a Literature Review. <i>Obesity Surgery</i> , 2021, 31, 1801-1809.	1.1	9
8	Integrative Genomic Analysis of Gemcitabine Resistance in Pancreatic Cancer by Patient-derived Xenograft Models. <i>Clinical Cancer Research</i> , 2021, 27, 3383-3396.	3.2	36
9	Comprehensive Analysis of Autophagy-Associated lncRNAs Reveal Potential Prognostic Prediction in Pancreatic Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 596573.	1.3	7
10	Construction of a prognostic model with histone modification-related genes and identification of potential drugs in pancreatic cancer. <i>Cancer Cell International</i> , 2021, 21, 291.	1.8	8
11	Early screening and diagnosis strategies of pancreatic cancer: a comprehensive review. <i>Cancer Communications</i> , 2021, 41, 1257-1274.	3.7	111
12	High-resolution Hi-C maps highlight multiscale 3D epigenome reprogramming during pancreatic cancer metastasis. <i>Journal of Hematology and Oncology</i> , 2021, 14, 120.	6.9	23
13	Advances in the epidemiology of pancreatic cancer: Trends, risk factors, screening, and prognosis. <i>Cancer Letters</i> , 2021, 520, 1-11.	3.2	128
14	The promoting effects of hsa_circ_0050102 in pancreatic cancer and the molecular mechanism by targeting miR-1182/NPSR1. <i>Carcinogenesis</i> , 2021, 42, 471-480.	1.3	9
15	The enhancement of glycolysis regulates pancreatic cancer metastasis. <i>Cellular and Molecular Life Sciences</i> , 2020, 77, 305-321.	2.4	206
16	High aspartate aminotransferase to alanine aminotransferase ratio on admission as risk factor for poor prognosis in COVID-19 patients. <i>Scientific Reports</i> , 2020, 10, 16496.	1.6	26
17	The prospect of serum and glucocorticoid-inducible kinase 1 (SGK1) in cancer therapy: a rising star. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592094094.	1.4	35
18	The role of histone methylation in the development of digestive cancers: a potential direction for cancer management. <i>Signal Transduction and Targeted Therapy</i> , 2020, 5, 143.	7.1	63

#	ARTICLE	IF	CITATIONS
19	Mucins in pancreatic cancer: A well-established but promising family for diagnosis, prognosis and therapy. <i>Journal of Cellular and Molecular Medicine</i> , 2020, 24, 10279-10289.	1.6	54
20	&lt;p&gt;GSTM3 Function and Polymorphism in Cancer: Emerging but Promising&lt;/p&gt;. <i>Cancer Management and Research</i> , 2020, Volume 12, 10377-10388.	0.9	17
21	Reprogramming of Amino Acid Metabolism in Pancreatic Cancer: Recent Advances and Therapeutic Strategies. <i>Frontiers in Oncology</i> , 2020, 10, 572722.	1.3	35
22	Glutathione S-Transferase Mu-3 Predicts a Better Prognosis and Inhibits Malignant Behavior and Glycolysis in Pancreatic Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 1539.	1.3	9
23	Stroma-Targeting Therapy in Pancreatic Cancer: One Coin With Two Sides?. <i>Frontiers in Oncology</i> , 2020, 10, 576399.	1.3	55
24	Prognostic and predictive value of a five-molecule panel in resected pancreatic ductal adenocarcinoma: A multicentre study. <i>EBioMedicine</i> , 2020, 55, 102767.	2.7	15
25	Mechanistic target of rapamycin in the tumor microenvironment and its potential as a therapeutic target for pancreatic cancer. <i>Cancer Letters</i> , 2020, 485, 1-13.	3.2	10
26	Transducin-Like Enhancer of Split-1 Inhibits Malignant Behaviors in vitro and Predicts a Better Prognosis in Pancreatic Ductal Adenocarcinoma. <i>Frontiers in Oncology</i> , 2020, 10, 576.	1.3	5
27	Expression, function and clinical application of stanniocalcinâ€1 in cancer. <i>Journal of Cellular and Molecular Medicine</i> , 2020, 24, 7686-7696.	1.6	31
28	Novel therapeutic strategies and perspectives for metastatic pancreatic cancer: vaccine therapy is more than just a theory. <i>Cancer Cell International</i> , 2020, 20, 66.	1.8	27
29	Metabolism of pancreatic cancer: paving the way to better anticancer strategies. <i>Molecular Cancer</i> , 2020, 19, 50.	7.9	192
30	High Expression of Cancer-Derived Glycosylated Immunoglobulin G Predicts Poor Prognosis in Pancreatic Ductal Adenocarcinoma. <i>Journal of Cancer</i> , 2020, 11, 2213-2221.	1.2	21
31	Neoantigen-based immunotherapy in pancreatic ductal adenocarcinoma (PDAC). <i>Cancer Letters</i> , 2020, 490, 12-19.	3.2	10
32	Hexosamine pathway inhibition overcomes pancreatic cancer resistance to gemcitabine through unfolded protein response and EGFR-Akt pathway modulation. <i>Oncogene</i> , 2020, 39, 4103-4117.	2.6	33
33	OLR1 Promotes Pancreatic Cancer Metastasis via Increased c-Myc Expression and Transcription of HMGA2. <i>Molecular Cancer Research</i> , 2020, 18, 685-697.	1.5	40
34	MiR-135a biogenesis and regulation in malignancy: a new hope for cancer research and therapy. <i>Cancer Biology and Medicine</i> , 2020, 17, 569-582.	1.4	26
35	High Expression of MUC15 Is Correlated with Poor Prognosis of Pancreatic Cancer and Promotes Migration, Invasion, and Chemo-Resistance In Vitro. <i>Medical Science Monitor</i> , 2020, 26, e926432.	0.5	2
36	Tumor microenvironment in chemoresistance, metastasis and immunotherapy of pancreatic cancer. <i>American Journal of Cancer Research</i> , 2020, 10, 1937-1953.	1.4	21

#	ARTICLE	IF	CITATIONS
37	Novel discoveries targeting gemcitabine-based chemoresistance and new therapies in pancreatic cancer: How far are we from the destination?. <i>Cancer Medicine</i> , 2019, 8, 6403-6413.	1.3	17
38	Long noncoding RNA GSTM3TV2 upregulates LAT2 and OLR1 by competitively sponging let-7 to promote gemcitabine resistance in pancreatic cancer. <i>Journal of Hematology and Oncology</i> , 2019, 12, 97.	6.9	88
39	MicroRNA-27a (miR-27a) in Solid Tumors: A Review Based on Mechanisms and Clinical Observations. <i>Frontiers in Oncology</i> , 2019, 9, 893.	1.3	41
40	Integrated analysis of gene expression and methylation profiles of novel pancreatic cancer cell lines with highly metastatic activity. <i>Science China Life Sciences</i> , 2019, 62, 791-806.	2.3	5
41	WT1 associated protein promotes metastasis and chemo-resistance to gemcitabine by stabilizing Fak mRNA in pancreatic cancer. <i>Cancer Letters</i> , 2019, 451, 48-57.	3.2	52
42	The dual functional role of MicroRNA-18a (miR-18a) in cancer development. <i>Clinical and Translational Medicine</i> , 2019, 8, 32.	1.7	55
43	Role of the microbiome in occurrence, development and treatment of pancreatic cancer. <i>Molecular Cancer</i> , 2019, 18, 173.	7.9	67
44	Non-invasive detection of pancreatic cancer by measuring DNA methylation of Basonuclin 1 and Septin 9 in plasma. <i>Chinese Medical Journal</i> , 2019, 132, 1504-1506.	0.9	9
45	Clinicopathological and prognostic significance of MKK4 and MKK7 in resectable pancreatic ductal adenocarcinoma. <i>Human Pathology</i> , 2019, 86, 143-154.	1.1	8
46	NF- $\kappa$ B in pancreatic cancer: Its key role in chemoresistance. <i>Cancer Letters</i> , 2018, 421, 127-134.	3.2	71
47	High expression of GRK3 is associated with favorable prognosis in pancreatic ductal adenocarcinoma. <i>Pathology Research and Practice</i> , 2018, 214, 228-232.	1.0	6
48	LAT2 regulates glutamine-dependent mTOR activation to promote glycolysis and chemoresistance in pancreatic cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2018, 37, 274.	3.5	83
49	High nuclear Survivin expression as a poor prognostic marker in pancreatic ductal adenocarcinoma. <i>Journal of Surgical Oncology</i> , 2018, 118, 1115-1121.	0.8	11
50	Gemcitabine exhibits a suppressive effect on pancreatic cancer cell growth by regulating processing of PVT1 to miR1207. <i>Molecular Oncology</i> , 2018, 12, 2147-2164.	2.1	36
51	Tumor microenvironment participates in metastasis of pancreatic cancer. <i>Molecular Cancer</i> , 2018, 17, 108.	7.9	361
52	Extracellular vesicles as mediators of the progression and chemoresistance of pancreatic cancer and their potential clinical applications. <i>Molecular Cancer</i> , 2018, 17, 2.	7.9	61
53	MiR-10a-5p targets TFAP2C to promote gemcitabine resistance in pancreatic ductal adenocarcinoma. <i>Journal of Experimental and Clinical Cancer Research</i> , 2018, 37, 76.	3.5	58
54	Plasminogen Activator Inhibitor 1 as a Poor Prognostic Indicator in Resectable Pancreatic Ductal Adenocarcinoma. <i>Chinese Medical Journal</i> , 2018, 131, 2947-2952.	0.9	11

#	ARTICLE	IF	CITATIONS
55	Pancreatic Cancer Progression Relies upon Mutant p53-Induced Oncogenic Signaling Mediated by NOP14. <i>Cancer Research</i> , 2017, 77, 2661-2673.	0.4	35
56	Expression of key mTOR pathway components in pancreatic ductal adenocarcinoma: A multicenter study for clinicopathologic and prognostic significance. <i>Cancer Letters</i> , 2017, 395, 45-52.	3.2	9
57	The underlying mechanisms of non-coding RNAs in the chemoresistance of pancreatic cancer. <i>Cancer Letters</i> , 2017, 397, 94-102.	3.2	50
58	WT1-associated protein is a novel prognostic factor in pancreatic ductal adenocarcinoma. <i>Oncology Letters</i> , 2017, 13, 2531-2538.	0.8	38
59	The Effect of Prophylactic Central Neck Dissection on Locoregional Recurrence in Papillary Thyroid Cancer After Total Thyroidectomy: A Systematic Review and Meta-Analysis. <i>Annals of Surgical Oncology</i> , 2017, 24, 2189-2198.	0.7	91
60	Potential functions and implications of circular RNA in gastrointestinal cancer (Review). <i>Oncology Letters</i> , 2017, 14, 7016-7020.	0.8	5
61	PD-1/PD-L1 and immunotherapy for pancreatic cancer. <i>Cancer Letters</i> , 2017, 407, 57-65.	3.2	235
62	Molecular Subtyping of Pancreatic Cancer: Translating Genomics and Transcriptomics into the Clinic. <i>Journal of Cancer</i> , 2017, 8, 513-522.	1.2	36
63	5-Hydroxymethylcytosine signatures in circulating cell-free DNA as diagnostic biomarkers for human cancers. <i>Cell Research</i> , 2017, 27, 1243-1257.	5.7	262
64	PIM-1 contributes to the malignancy of pancreatic cancer and displays diagnostic and prognostic value. <i>Journal of Experimental and Clinical Cancer Research</i> , 2016, 35, 133.	3.5	46
65	c-Fos/ERK promotes the progression from pancreatic intraepithelial neoplasia to pancreatic ductal adenocarcinoma. <i>Oncology Reports</i> , 2016, 36, 3413-3420.	1.2	9
66	Activator protein 1 promotes gemcitabine-induced apoptosis in pancreatic cancer by upregulating its downstream target Bim. <i>Oncology Letters</i> , 2016, 12, 4732-4738.	0.8	6
67	Plasma miRNAs Effectively Distinguish Patients With Pancreatic Cancer From Controls. <i>Annals of Surgery</i> , 2016, 263, 1173-1179.	2.1	73
68	Insights into the distinct roles of MMP-11 in tumor biology and future therapeutics (Review). <i>International Journal of Oncology</i> , 2016, 48, 1783-1793.	1.4	84
69	G-protein-coupled receptor kinase 2 in pancreatic cancer: clinicopathologic and prognostic significance. <i>Human Pathology</i> , 2016, 56, 171-177.	1.1	18
70	The Effect of Body Mass Index on Surgical Outcomes in Patients Undergoing Pancreatic Resection. <i>Pancreas</i> , 2016, 45, 796-805.	0.5	25
71	Long non-coding RNA PVT1 and cancer. <i>Biochemical and Biophysical Research Communications</i> , 2016, 471, 10-14.	1.0	119
72	Filamin A: Insights into its Exact Role in Cancers. <i>Pathology and Oncology Research</i> , 2016, 22, 245-252.	0.9	76

#	ARTICLE	IF	CITATIONS
73	Expression and Significances of MTSS1 in Pancreatic Cancer. <i>Pathology and Oncology Research</i> , 2016, 22, 7-14.	0.9	14
74	miR-497 expression, function and clinical application in cancer. <i>Oncotarget</i> , 2016, 7, 55900-55911.	0.8	57
75	CXCL12-CXCR7 axis contributes to the invasive phenotype of pancreatic cancer. <i>Oncotarget</i> , 2016, 7, 62006-62018.	0.8	40
76	Challenges in detecting pre-malignant pancreatic lesions during acute pancreatitis using a serum microRNA assay: a study based on <i>KrasG12D</i> transgenic mice. <i>Oncotarget</i> , 2016, 7, 22700-22710.	0.8	8
77	Analysis of clinical characteristics and treatment of pancreatic cystic tumors. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association</i> , Beijing Institute for Cancer Research, 2016, 28, 519-527.	0.7	0
78	Catechol-O methyltransferase, a new target for pancreatic cancer therapy. <i>Cancer Science</i> , 2015, 106, 576-583.	1.7	15
79	Expression of c-fos Was Associated with Clinicopathologic Characteristics and Prognosis in Pancreatic Cancer. <i>PLoS ONE</i> , 2015, 10, e0120332.	1.1	20
80	Chemotherapy-Induced miRNA-29c/Catenin $\beta$ Signaling Suppresses Metastasis in Gastric Cancer. <i>Cancer Research</i> , 2015, 75, 1332-1344.	0.4	58
81	MIR-1178 Promotes the Proliferation, G1/S Transition, Migration and Invasion of Pancreatic Cancer Cells by Targeting CHIP. <i>PLoS ONE</i> , 2015, 10, e0116934.	1.1	19
82	HLA-G impairs host immune response and predicts poor prognosis in pancreatic cancer. <i>American Journal of Translational Research (discontinued)</i> , 2015, 7, 2036-44.	0.0	18
83	Nuclear translocation of fibroblast growth factor receptor 3 and its significance in pancreatic cancer. <i>International Journal of Clinical and Experimental Pathology</i> , 2015, 8, 14640-8.	0.5	9
84	Alteration of the Intrinsic Apoptosis Pathway Is Involved in Notch-induced Chemoresistance to Gemcitabine in Pancreatic Cancer. <i>Archives of Medical Research</i> , 2014, 45, 15-20.	1.5	16
85	PIM kinases: an overview in tumors and recent advances in pancreatic cancer. <i>Future Oncology</i> , 2014, 10, 865-876.	1.1	33
86	Insulin-Like Growth Factor 1 Receptor (IGF-1R) as a Target of MiR-497 and Plasma IGF-1R Levels Associated with TNM Stage of Pancreatic Cancer. <i>PLoS ONE</i> , 2014, 9, e92847.	1.1	36
87	An Increased Total Resected Lymph Node Count Benefits Survival following Pancreas Invasive Intraductal Papillary Mucinous Neoplasms Resection: An Analysis Using the Surveillance, Epidemiology, and End Result Registry Database. <i>PLoS ONE</i> , 2014, 9, e107962.	1.1	5
88	The Effect of Pylorus Removal on Delayed Gastric Emptying after Pancreaticoduodenectomy: A Meta-Analysis of 2,599 Patients. <i>PLoS ONE</i> , 2014, 9, e108380.	1.1	25
89	MiR-497 downregulation contributes to the malignancy of pancreatic cancer and associates with a poor prognosis. <i>Oncotarget</i> , 2014, 5, 6983-6993.	0.8	76
90	Krüppel-like factor 8 is a potential prognostic factor for pancreatic cancer. <i>Chinese Medical Journal</i> , 2014, 127, 856-9.	0.9	5

#	ARTICLE	IF	CITATIONS
91	Genome-wide screen identifies PVT1 as a regulator of Gemcitabine sensitivity in human pancreatic cancer cells. <i>Biochemical and Biophysical Research Communications</i> , 2011, 407, 1-6.	1.0	118
92	Core signaling pathways and new therapeutic targets in pancreatic cancer. <i>Chinese Medical Journal</i> , 2010, 123, 1210-5.	0.9	6
93	Plasma microRNA panels to diagnose pancreatic cancer: Results from a multicenter study. <i>Oncotarget</i> , 0, 7, 41575-41583.	0.8	46